Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients

NCT02022709 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2022-09-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficiency of SSRIs(Selective Serotonin Reuptake Inhibitor) ,ERP(Exposure and Response Prevention) and the combination of the two therapies for OCD(Obsessive-Compulsive Disorder) patients ,at the same time, to find out the biological or psychological predictors of treatment response in Chinese population.

Conditions

  • Obsessive-Compulsive Disorder
  • Anxiety Disorders
  • Mental Disorders

Interventions

DRUG

Fluoxetine

The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

DRUG

Sertraline

The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

DRUG

Paroxetine

The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

DRUG

Citalopram

The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

DRUG

Fluvoxamine

The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

BEHAVIORAL

Exposure and Response Prevention

8 exposure and response prevention (ERP) sessions,once a week

Sponsors & Collaborators

  • Shanghai Municipal Science and Technology Commission

    collaborator OTHER_GOV
  • Shanghai Jiao Tong University School of Medicine

    collaborator OTHER
  • Shanghai Mental Health Center

    lead OTHER

Principal Investigators

  • Zhen Wang, Ph.D, M.D · Shanghai Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-11-18
Completion
2018-03-13

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02022709 on ClinicalTrials.gov